Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;29(8):e70104.
doi: 10.1002/ejp.70104.

Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study

Affiliations

Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study

Kristel Berati et al. Eur J Pain. 2025 Sep.

Abstract

Introduction: Central post stroke pain (CPSP) is attributed to vascular lesions of the central somatosensory system, including the thalamus.

Objective: A better characterisation of clinical findings in patients with CPSP after thalamic stroke can facilitate research and treatment of this refractory pain syndrome. We aimed to quantify somatosensory abnormalities in CPSP patients after thalamic stroke.

Methods: Sixteen patients with CPSP after thalamic stroke, 14 patients with a history of thalamic stroke without any pain (stroke control patients, SCP) and 12 healthy controls (HC) underwent detailed clinical examination, standardised quantitative sensory testing (QST) and a pain questionnaire. QST results were compared to age and sex adjusted reference data to obtain z-scores. Group comparisons were performed with one-way analysis of variance.

Results: Temperature perception did not differ in CPSP patients, apart from thermal sensory limen (higher in CPSP vs. HC but no difference vs. SCP). Patients with CPSP showed higher mechanical detection thresholds compared to SCP (Δ = 1.26, p = 0.017, no difference vs. HC) and they were more sensitive to mechanical pain than SCP (lower mechanical pain thresholds vs. SCP: Δ = -1.32, p = 0.014, no difference vs. HC).

Conclusion: Our results indicate somatosensory abnormalities in patients with CPSP after thalamic stroke, associated with the perception of mechanical stimuli. A short somatosensory screening including mechanical perception may contribute to an accurate diagnosis of this debilitating condition.

Significance statement: Thalamic CPSP is very rare, thus our data contribute to the clinical and sensory phenotyping of patients suffering from this debilitating condition. We did not find abnormalities in thermal measures, but only mechanical thresholds in our cohort, suggesting that not only changes in temperature perception are necessary for the development of pain after thalamic stroke. Our findings suggest that a short QST protocol including mechanical testing using von Frey filaments and pin-prick-stimulators may be useful in the diagnosis of thalamic CPSP.

Keywords: CPSP; QST; mechanical pain sensitivity; phenotyping; thalamic pain; thalamic stroke.

PubMed Disclaimer

Conflict of interest statement

Kristel Berati, Priska Zuber and Kean Schoenhoelzer do not have conflicts of interest to declare. Lukas S. Enz has received funding from the Swiss National Science Foundation (323530_171139). Katarina Alexandra Ebner received compensation for advisory board (Lundbeck), which was used for research in the University Hospital of Basel. Federico Burguet Villena received travel support form TEVA. Laura Gaetano is currently an employee of Novartis AG. Ludwig Kappos: Institutional research support: steering committee, advisory board, consultancy fees: Actelion, Bayer HealthCare, Biogen, Bristol Myers Squibb, Genzyme, Janssen, Japan Tobacco, Merck, Novartis, Roche, Sanofi, Santhera, Shionogi, and TG Therapeutics, speaker fees: Bayer HealthCare, Biogen, Merck, Novartis, Roche, and Sanofi; support of educational activities: Allergan, Bayer HealthCare, Biogen, CSL Behring, Desitin, Genzyme, Merck, Novartis, Roche, Pfizer, Sanofi, Shire, and Teva; license fees for Neurostatus products; and grants: Bayer HealthCare, Biogen, European Union, Innosuisse, Merck, Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation. Stefano Magon is currently an employee of F. Hoffmann‐La Roche. Athina Papadopoulou received speaker‐fees/fees for advisory boards/consulting activities from Sanofi‐Genzyme, Eli Lilly, AbbVie, Lundbeck and TEVA and travel support from Bayer AG, Teva and Hoffmann‐La Roche. Her research was supported by the University‐ and University Hospital of Basel, the Swiss Multiple Sclerosis Society, the “Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung”, the “Freie Akademische Gesellschaft Basel” and the Swiss National Science Foundation (Project number: P300PB_174480). During the current research work, Athina Papadopoulou was supported by the Swiss National Science Foundation (PZ00P3_216468). Till Sprenger received research grants from the Swiss MS Society, Novartis Pharmaceuticals Switzerland, EFIC‐Grünenthal grant, and Swiss National Science Foundation. The current (DKD Helios Klinik Wiesbaden) or previous (University Hospital Basel) institutions of Till Sprenger have received payments for speaking or consultation from: Biogen Idec, Eli Lilly, Allergan, Actelion, ATI, Mitsubishi Pharma, Novartis, Genzyme and TEVA.

Figures

FIGURE 1
FIGURE 1
Pain characteristics in the CPSP group. The description of different pain characteristics is based on the patients' answers in the standardised pain questionnaire (“Deutscher Schmerzfragebogen”). (a) pain character, (b) accompanying symptoms (Skin hypersensitivity refers to the area of pain), (c) affective description, (d) worsening factors (Body posture refers to prolonged sitting/standing/walking) and (e) alleviating factors. Multiple answers were possible, n = number of participants who gave at least one answer (for some questions 1–2 missing).
FIGURE 2
FIGURE 2
Z‐score values of all QST parameters per group. The age‐ and sex‐adjusted Z‐score values of all QST parameters (based on previously published reference data (Magerl et al. 2010)) are displayed in boxplots per study group. The following QST parameters are shown: (a) cold detection threshold (b) warm detection threshold (c) temperature sensory limen (d) cold pain threshold (e) heat pain threshold (f) mechanical detection threshold (g) mechanical pain threshold (h) mechanical pain sensitivity (i) dynamic mechanical allodynia (j) wind‐up‐ratio (k) vibration detection threshold (l) pressure pain threshold. Note that the Z score values which were outside the 95% CI are depicted in grey. The only parameters showing significant group‐differences were (c) temperature sensory limen, (f) mechanical detection‐ and (g) mechanical pain thresholds, the p‐values of these comparisons are shown in the figure.°C, Degree Celsius; CPSP, Central post stroke pain patients; HC, Healthy controls; mN, Millinewton; SCP, Stroke Control patients.
FIGURE 3
FIGURE 3
Topography of pain and heatmap of pain distribution in the CPSP group. (a) Visualisation of Heatmap showing the distribution of pain for specific body regions across all CPSP patients. Pain localised in the lower leg (n = 4), face, head (n = 5), upper leg (n = 7), trunk (n = 8), lower arm, foot (n = 10), hand, shoulder (n = 12) and upper arm (n = 14). Please note that the body areas affected by pain were assessed by a standardised pain questionnaire (“Deutscher Schmerzfragebogen”, DGSS, created by the German Pain Association, copyright: https://www.schmerzgesellschaft.de/). (b) Visualisation of Topography of pain and positive/negative sensory symptoms in the CPSP group “Predominant pain” (in red) refers to the body region with the most severe/frequent neuropathic pain. “All pain” (in pink) refers to any body region where the patients experienced pain, not related to the predominant neuropathic pain. “Hypesthesia” (yellow) refers to body regions that showed reduced sensitivity to light touch at bed‐side neurological examination, while “hyperesthesia” (blue bars) refers to positive symptoms revealed or reported by the patients at bed‐side examination (including paresthesia, dysesthesias, hyperesthesia for light touch and allodynia). All illustrations are standardised to show all symptoms on the left side.

Similar articles

References

    1. Andersen, G. , Vestergaard K., Ingeman‐Nielsen M., and Jensen T. S.. 1995. “Incidence of Central Post‐Stroke Pain.” Pain 61: 187–193. 10.1016/0304-3959(94)00144-4. - DOI - PubMed
    1. Asseyer, S. , Panagoulas E., Maidhof J., et al. 2025. “Prediction of Central Post‐Stroke Pain by Quantitative Sensory Testing.” Annals of Neurology 97: 507–520. 10.1002/ana.27138. - DOI - PMC - PubMed
    1. Barbosa, L. M. , Da Silva V. A., De Lima Rodrigues A. L., et al. 2022. “Dissecting Central Post‐Stroke Pain: A Controlled Symptom‐Psychophysical Characterization.” Brain Communications 4: fcac090. 10.1093/braincomms/fcac090. - DOI - PMC - PubMed
    1. Bogousslavsky, J. , Regli F., and Uske A.. 1988. “Thalamic Infarcts: Clinical Syndromes, Etiology, and Prognosis.” Neurology 38: 837. 10.1212/WNL.38.6.837. - DOI - PubMed
    1. Boivie, J. , Leijon G., and Johansson I.. 1989. “Central Post‐Stroke Pain—A Study of the Mechanisms Through Analyses of the Sensory Abnormalities.” Pain 37: 173–185. 10.1016/0304-3959(89)90128-0. - DOI - PubMed

LinkOut - more resources